Published: Thu, May 18, 2017
Sci-tech | By Carrie Guzman

Integra Lifesciences Holdings Corp (IART) Updates FY17 Earnings Guidance


The business is expected to issue its next earnings results on Thursday, July 27th.

Edwards Lifesciences Corp (NYSE:EW) has insider ownership of 2.37% and institutional ownership of 83.99%.

About 1.17 million shares traded. Earnings, with 20 analysts believing the company would generate an Average Estimate of $0.88. The life sciences company reported $0.39 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by $0.01. It has a return on equity (ROE) of 25.00%. The firm had revenue of $883.50 million for the quarter, compared to analyst estimates of $776.51 million. While in the same Quarter Previous year, the Actual EPS was $0.76. Integra Lifesciences Holdings Corp's revenue for the quarter was up 9.2% compared to the same quarter a year ago.

A number of other hedge funds have also added to or reduced their stakes in the stock. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $48.00 target price (up previously from $46.00) on shares of Integra Lifesciences Holdings Corp in a research note on Tuesday, May 2nd.

Edwards Lifesciences Corporation has a consensus outperform rating from 21 Wall Street analysts, and the number of shares now sold short amount to at least 0.98% of shares outstanding. Oppenheimer Holdings Inc. reaffirmed a "buy" rating on shares of Integra Lifesciences Holdings Corp in a research report on Wednesday, March 22nd. Zacks Investment Research upgraded Edwards Lifesciences Corp from a "hold" rating to a "buy" rating and set a $127.00 price target on the stock in a research report on Tuesday. Finally, Barclays PLC reissued an "equal weight" rating and set a $42.00 price objective (down from $84.00) on shares of Integra Lifesciences Holdings Corp in a research report on Friday, January 13th.

On 4/5/2017 Donald E. Bobo, Jr., VP, sold 13,720 with an average share price of $93.58 per share and the total transaction amounting to $1,283,917.60. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. The shares were sold at an average price of $45.89, for a total transaction of $718,545.62. Company insiders own 21.40% of the company's stock. The disclosure for this sale can be found here. Synovus Financial Corp increased its stake in Edwards Lifesciences Corp by 3.9% in the third quarter. Following the completion of the transaction, the director now owns 70,154 shares in the company, valued at $3,219,367.06. BlackRock Inc. increased its stake in shares of Integra Lifesciences Holdings Corp by 307,726.8% in the first quarter. TCI Wealth Advisors Inc. now owns 1,044 shares of the medical research company's stock worth $126,000 after buying an additional 244 shares in the last quarter.

Nine injured in altercation at Turkish Embassy in Washington
The State Department has also expressed concern to Turkey in the "strongest possible terms" after the clashes in Washington . Video from the scene shows a brief but intense altercation involving dozens of people in front of the embassy.

Edwards Lifesciences Corp is now covered by analysts at Goldman Sachs Group Inc.

BLB&B Advisors LLC held its stake in Edwards Lifesciences Corp (NYSE:EW) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. Fuller & Thaler Asset Management Inc. now owns 1,500 shares of the medical research company's stock worth $181,000 after buying an additional 700 shares in the last quarter. Advantage Investment Management LLC bought a new position in shares of Edwards Lifesciences Corp during the fourth quarter worth about $145,000. DnB Asset Management AS now owns 18,446 shares of the medical research company's stock valued at $2,224,000 after buying an additional 400 shares during the period.

Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at 46.69 on Thursday. The stock closing price is now trading upward to its 50 day moving average with change of 15.11%, escalated to its 20 day moving average with figure of 6.76% and above its 200 day moving average with value 12.34%. The stock has a market cap of $3.53 billion, a P/E ratio of 55.58 and a beta of 0.80. Edwards Lifesciences Corp has a 1-year low of $81.12 and a 1-year high of $121.75.

"WARNING: "$282.89 Million in Sales Expected for Integra Lifesciences Holdings Corp (IART) This Quarter" was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and reposted in violation of USA and global trademark and copyright legislation. As of this writing, Edwards Lifesciences Corporation's RSI stands at 72.54. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve.

Like this: